The ReProgram

🎬 EPISODE OVERVIEW

Can you actually eat like a centenarian to extend your life? We examine the evidence behind dietary habits and aging.Dr. Paola Sebastiani joins us to discuss the complexities of longevity science and why the current diet of someone who has lived to 100 may not reflect the factors that helped them reach that age. We unpack how metabolomics provides clues about physiological decline, while emphasizing that a single blood marker does not establish cause and effect for long-term health.Our conversation addresses common myths regarding protein intake and the role of genetics in exceptional longevity. By analyzing the data from the New England Centenarian Study, we separate biological mechanisms from marketing claims to understand what truly supports healthy aging. We also look at the limitations of biological age tests and why standardization remains a critical challenge in current research.If you value longevity science without the hype, subscribe to The ReProgram for weekly evidence-based breakdowns. What is one belief about food and aging you would be willing to reconsider?

👤 ABOUT THE SPEAKER

Dr. Paola Sebastiani is a Professor at Tufts University School of Medicine and Director of the Tufts CTSI Biostatistics, Epidemiology, and Research Design Center. A biostatistician studying genetics and exceptional longevity, she and her group lead data analyses for the New England Centenarian Study.

Official profile: https://disc.tufts.edu/paola-sebastiani

🔑 KEYWORDS

Paola Sebastiani • Centenarians • Nutrition • Metabolomics • Protein • Healthy Aging • Longevity Genetics • Biological Age

📌 KEY TAKEAWAYS

• Metabolites offer clues about aging, but a blood marker does not by itself establish cause and effect.

• A centenarian’s current diet may differ from the diet they followed decades earlier. Longitudinal studies matter.

• Protein findings from animal studies do not automatically translate to older adults. Sebastiani also cautions against assuming more is always better.

• Centenarians are a diverse group; no single food or genetic explanation captures every path to exceptional longevity.

• Sebastiani emphasizes standardization and interpretation when discussing biological-age tests.

🎙️ THE REPROGRAM PERSPECTIVE

A longevity headline can turn an association into an apparent prescription. We need to ask who was studied, what was measured, and whether a finding predicts better health or simply accompanies it.The goal is to preserve health, function, and independence—not just chase a number.

⏱️ CHAPTERS

00:00 Should we eat like a centenarian?

00:58 Introducing Paola Sebastiani

01:57 An unexpected route into longevity research

03:56 The Cell Reports paper and metabolomics

06:04 Nutrition and the dark-chocolate connection

07:19 Why following people over time matters

09:01 Essential amino acids and dietary changes

14:12 What do centenarians eat?

18:31 Protein restriction versus aging well

20:39 Protein sources and pumpkin seeds

22:40 Dietary fats

23:26 Genes, nutrition, and longevity families

26:57 Centenarian misconceptions

27:43 Biological-age tests

28:57 Healthspan and longevity interventions

30:05 The unresolved genetics of longevity

31:08 Activity tracking and personal habits

33:21 What aging well means

34:20 Closing thoughts

📝 NOTES AND REFERENCES

1. Sebastiani P et al. Metabolite signatures of chronological age, aging, survival, and longevity. Cell Reports (2024);43(11):114913.https://doi.org/10.1016/j.celrep.2024.114913Open-access paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11656345/

💬 JOIN THE CONVERSATION

What is one belief about food and aging you would be willing to reconsider?

Subscribe to The ReProgram for more conversations about livingwell.

https://www.youtube.com/@ReProgramPodcast

Longevity Biology Without the Hype

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

Does your fish oil capsule deserve its reputation? In Episode 31, I review omega-3s for heart health, cognition, and healthy aging, then give five evidence scores and an overall C+.We examine VITAL, REDUCE-IT, STRENGTH, newer DHA research, aging clocks, and safety. Eating fish, taking supplements, and using prescription omega-3s are different questions.

🔑 KEYWORDS

Omega-3 • Fish Oil • EPA • DHA • Triglycerides • Cognition • Aging Clocks • Atrial Fibrillation • Longevity

📌 KEY TAKEAWAYS

• Triglyceride lowering: 5/5 at studied therapeutic doses.

• Routine cardiovascular prevention in generally healthy adults: 2/5. Prescription EPA in selected high-risk patients is a separate clinical decision.

• Preventing cognitive decline in generally healthy older adults: 1/5.

• Epigenetic aging clocks: 2/5. Small changes in clock estimates do not establish longer life.

• Extending human lifespan through routine supplementation: 1/5.

• Overall: C+ for routine OTC fish oil as a healthy-aging intervention; this is my assessment, not a mathematical average. Dose, formulation, and baseline risk matter.

🎙️ THE REPROGRAM PERSPECTIVE

A biological mechanism or improved test result is a starting point. Ask whether the evidence shows better health, function, or survival in people like you. Educational discussion; understand prescribed treatment with your clinician before making changes.

⏱️ CHAPTERS

00:00 What has fish oil earned?

00:55 The Scorecard framework

01:16 Fish, supplements, and prescription products

01:56 Read the EPA and DHA label

02:27 Triglycerides: the strongest evidence

03:43 VITAL and heart prevention

04:39 REDUCE-IT and prescription EPA0

5:50 STRENGTH and conflicting results

07:08 Brain health and the DHA trials

08:34 DO-HEALTH and aging clocks

09:59 Heart-rhythm risk and interactions

11:37 Five claims, five scores

13:22 The C+ verdict and its limits

14:27 Questions to ask about your supplement

15:31 Closing perspective

💬 JOIN THE CONVERSATION

If you take fish oil, what benefit are you hoping for—and does the evidence match that goal?

Subscribe to The ReProgram: https://www.youtube.com/@ReProgramPodcast

Longevity Biology Without the Hype.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

Can a younger clock score translate into better health?In Episode 30, I sit down with Dr. Steve Horvath to explore epigenetic clocks, biological-age claims, and his vision for rejuvenation.

We discuss why there are so many clocks, what stands between research and patient care, prevention, and why progress may come one organ at a time

.👤 ABOUT THE SPEAKER

Dr. Steve Horvath is Professor of Medicine and Director of Aging Biology Research at UCLA’s David Geffen School of Medicine. A geroscientist and biostatistician, he developed the influential 2013 multi-tissue DNA methylation clock.Lab profile: https://horvathaginglab.org/

🔑 KEYWORDS

Steve Horvath • Epigenetic Clocks • DNA Methylation • Biological Age • Rejuvenation • Prevention • Aging Biomarkers • Geroscience

📌 KEY TAKEAWAYS

• Different aging clocks can produce different results. Horvath argues for transparent reporting across multiple clocks.

• Dramatic age-reversal claims deserve scrutiny; a younger test result needs meaningful interpretation.

• Horvath sees promise in clinical use, while emphasizing that routine patient care is not there yet.

• Rejuvenation is connected to prevention: the aim is to preserve health before disease develops.

• A realistic path may focus on individual organs rather than a single treatment for the entire body.

🎙️ THE REPROGRAM PERSPECTIVE

Better measurement can sharpen the questions we ask about aging. The next challenge is connecting those measurements to outcomes that matter to people.Our focus: what changed, how reliably was it measured, and what does it mean for health and function?

⏱️ CHAPTERS

00:00 Can we measure and reverse aging?

00:51 Introducing Steve Horvath

01:40 Reinventing a research career

05:28 Why are there so many aging clocks?

07:51 Bringing clocks into clinical practice

09:16 Evaluating age-reversal claims

11:31 Rejuvenation and prevention

14:37 What does rejuvenation mean?

16:26 One organ at a time

18:36 Lifestyle, testing, and perspective

20:57 Closing thoughts

📝 NOTES AND REFERENCES

Related papers featured in the edit:

1. Horvath S. DNA methylation age of human tissues and cell types. Genome Biology (2013).https://doi.org/10.1186/gb-2013-14-10-r115

2. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics (2018).https://doi.org/10.1038/s41576-018-0004-3

3. Lu Y et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature (2020).https://doi.org/10.1038/s41586-020-2975-4The Lu study is preclinical mouse research, not evidence of whole-body age reversal in humans.

💬 JOIN THE CONVERSATION

What would convince you that an intervention truly rejuvenates: a younger clock score, better organ function, or both?

Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcast

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

Why do some animals live so much longer than others—and what can they teach us about healthier human aging?In Episode 29 of The ReProgram, I sit down with Dr. Steve Austad to explore nature’s longevity clues, why women tend to outlive men, and what would count as convincing evidence that an intervention slows aging.We discuss aging “speedometers,” the difference between lifespan and healthspan, the case for funding geroscience, and how to evaluate biological-age claims without losing sight of enjoying life.

👤 ABOUT THE SPEAKER

Dr. Steven N. Austad is a Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research at the University of Alabama at Birmingham, and Scientific Director of the American Federation for Aging Research. His research explores the comparative biology of aging, using differences among species to understand longevity and identify potential ways to preserve human health.Official profile: https://www.uab.edu/icar/about/icar-leadership/steven-n-austad-phd

🔑 KEYWORDS

Longevity • Comparative Biology • Steve Austad • Healthspan • Aging Rate Indicators • Biological Age • Geroscience • Sex Differences • DunedinPACE

📌 KEY TAKEAWAYS

• Long-lived animals offer clues about aging biology and potential directions for human research.

• A finding in animals is a starting point; demonstrating a meaningful benefit in people requires further testing.

• Measuring biological age and measuring the pace of aging are different questions. A change in a test result alone does not prove that an intervention slows aging.

• Healthspan puts the focus on maintaining function and quality of life.

• Evaluating longevity claims means asking what was measured, what changed, and whether the evidence supports the conclusion.

🎙️ THE REPROGRAM PERSPECTIVE

Nature shows that the pace of aging varies enormously across species. Understanding the biology behind those differences could reveal ways to preserve human health.For The ReProgram, the next step is to connect those clues to rigorous tests: does an intervention produce a reproducible improvement in function, resilience, or healthy years of life? Aging measurements are valuable when they help answer that question. The goal is more time living well, with evidence strong enough to guide our choices.

⏱️ CHAPTERS

00:00 What nature can teach us

00:28 The ReProgram

00:36 Introducing Steve Austad

01:23 Opossums and the origins of an aging scientist

02:44 What is aging?

03:43 Evolution and longevity

04:46 Learning from long-lived animals

07:24 Why women tend to live longer

12:03 What would count as evidence of slower aging?

13:13 From animal findings to human benefits

14:31 Aging clocks versus aging speedometers

18:49 Lifespan and healthspan

19:44 Lightning round: the XPRIZE

21:19 Funding aging research

22:43 Evaluating biological-age claims

24:01 Enjoying life while studying longevity

25:13 Closing thoughts

📝 NOTES AND REFERENCES

1. Austad SN, Kaeberlein M, Miller RA. Aging rate indicators and the search for anti-aging drugs. Frontiers in Science (2026).https://doi.org/10.3389/fsci.2026.1821393

2. Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife (2022);11:e73420.https://doi.org/10.7554/eLife.73420Clarification: DunedinPACE uses DNA methylation to estimate the pace of aging. The on-screen explanation clarifies the interview’s reference to an RNA marker.

3. XPRIZE Healthspan — official competition information:https://www.xprize.org/competitions/healthspan

💬 JOIN THE CONVERSATION

What would convince YOU that a treatment truly slows aging: a biological-age test, better physical function, or something else?

Tell us which result matters most—and why.If you value longevity science without the hype, subscribe to The ReProgram.https://www.youtube.com/@ReProgramPodcast

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

The Longevity Consortium is mapping the biology of aging. We review the NIH-funded research aiming to delay chronic disease.The NIH-supported Longevity Consortium is a massive effort to understand the biology of aging to reduce risks of cancer, dementia, and frailty. We examine their five core focus areas, ranging from exceptional longevity cohorts to candidate drug screening. Dr. Nik Schork and Dr. George Murphy break down the current strategy for targeting age-related decline.This initiative represents a distinct pivot in geroscience research, moving beyond single-pathway hypotheses to look at systemic biological markers. We analyze the scope of these projects to see which are likely to yield clinical outcomes and which remain preliminary explorations. Understanding the biology of aging remains a complex challenge, but this consortium provides a structural framework for how we might eventually mitigate chronic disease.

🔑 KEYWORDS

Longevity • Healthspan • Aging Biology • NIH • NIA • Longevity Consortium • Nik Schork • Centenarians • Human Cell Models • Geroscience

📌 KEY TAKEAWAYS

◆ Healthspan and lifespan are related goals, but improving a biological measurement is not the same as proving that people live longer.

◆ Exceptional longevity may reflect protective biology alongside disease-risk variants, as well as behavior and environmental exposures.

◆ The five projects connect discovery with functional testing. A genetic association still needs a biological explanation and follow-up experiments.

◆ Human cell models help isolate a signal; animal studies and human research test whether it matters in a more complex system.

◆ Public funding supports collaboration across disciplines and exploratory work that may not begin with a single commercial product.

◆ Shared aging mechanisms could offer opportunities to address multiple diseases. That is a research goal, not a claim that a proven universal treatment exists.

◆ A critical approach to evidence matters when evaluating claims about measuring or reversing biological age.

🎙️ THE REPROGRAM PERSPECTIVE

Longevity Biology Without the Hype. The important question is not simply whether an intervention changes a marker, but whether it produces a meaningful, reproducible benefit for people. This conversation follows the research pathway; it does not present a finished anti-aging treatment.⏱️

CHAPTERS

00:00 Can we slow aging?

01:08 Meet Dr. Nik Schork

02:01 From philosophy to longevity science

03:53 What is the Longevity Consortium?

05:24 Healthspan versus lifespan

06:31 Why team science matters07:55 Project 1: Predicting human longevity

09:23 Project 2: Lessons from long-lived species

12:46 Project 3: Centenarians and resilience

14:50 Disease-risk genes and exceptional longevity

16:20 Project 4: From genes to candidate drugs

19:04 Project 5: Testing ideas in human cells

21:42 Connecting a discovery across the consortium

24:45 The challenge of proving human benefit

26:38 What public funding makes possible

29:12 Shared aging mechanisms and the public payoff

32:13 What success could look like

35:02 Lightning round: Can aging biology be modified?

36:12 Misconceptions about publicly funded science

37:24 How to evaluate longevity claims

39:13 How the science shapes Nik’s own health choices

41:50 Closing the conversation

42:48 The ReProgram takeaway

📝 SELECTED NOTES AND REFERENCES

1. Longevity Consortium overview. Official description of the research program and its integrated approach.https://www.longevityconsortium.org/overview/

2. Longevity Consortium projects and resources. Explore the five projects and their leadership. https://www.longevityconsortium.org/

▶

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

🎬 EPISODE OVERVIEW

Could the compound in magic mushrooms influence how we age? Psilocybin research is producing intriguing findings, but changing brain activity, treating depression and extending human life are very different claims.In Episode 27, Dr. George Murphy puts psilocybin through The ReProgram Scorecard. He examines experiments in human cells and aged mice, brain imaging and plasticity studies, inflammatory markers, and clinical research on depression.The episode also explores preliminary Parkinson’s and Alzheimer’s reports, why a change in a biomarker is not the same as preventing disease, and what it would take to establish a meaningful benefit for older adults.The verdict: psilocybin deserves serious investigation. The evidence discussed does not establish human life extension or dementia prevention. Its strongest clinical argument remains mental health treatment in carefully supervised settings.

🔑 KEYWORDS

Psilocybin • Psilocin • Psychedelics • Longevity • Brain Plasticity • Depression • Inflammation • Cognitive Aging • ReProgram Scorecard

📌 KEY TAKEAWAYS

• The longevity headline needs context. More cell divisions in a dish and improved mouse survival at a study endpoint do not demonstrate longer human life.

• Brain changes are measurable. Plasticity and altered network coordination do not establish a universal neurotransmitter reset or a rejuvenated brain.• Inflammation findings vary. The marker, population and timing matter; sustained clinical benefit remains an open question.

• Preliminary observations cannot establish dementia prevention. Small uncontrolled studies and an Alzheimer’s case report provide research questions, not proof of disease reversal.

• Mental health benefits deserve their own assessment. Randomized evidence is encouraging, while durability, patient selection, support and adverse effects still matter.

• Evidence grades are claim specific. A strong plasticity score cannot fill the evidence gap for dementia prevention or human life extension.

🎙️ THE REPROGRAM PERSPECTIVE

Psilocybin’s potential is worth investigating. The next step is to establish which changes help, who benefits, how long benefits last, and what they cost in risk.Brain plasticity and network change: 4/5Mental health benefit in supervised treatment: 3/5Reducing inflammation: 2/5Preventing cognitive decline: 1/5Extending human lifespan: 1/5These are evidence grades, not treatment recommendations. They are not averaged into an overall score. The episode does not establish a longevity dosing regimen or justify self-directed use.

⏱️ CHAPTERS

00:00 Could psilocybin change how we age?

01:12 Five different claims

01:54 Cells mice and the longevity headline

03:19 What brain plasticity actually means

05:06 Human brain changes and study limitations

05:52 Neurotransmitters and the chemical reset claim

07:00 Inflammation signals and conflicting findings

09:00 Cognitive decline Parkinson's and Alzheimer's

10:58 Depression benefits durability and risks

11:59 The five part ReProgram Scorecard

13:26 What would change the evidence grades

14:03 Safety and the final verdict

📝 SELECTED NOTES AND REFERENCES1. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging. 2025. Cell and aged female mouse experiments behind the longevity discussion.https://doi.org/10.1038/s41514-025-00...

2. Psilocybin desynchronizes the human brain. Nature. 2024. Repeated imaging of brain network changes in seven healthy adults.https://doi.org/10.1038/s41586-024-07...

3. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell. Published online December 2025. Mouse research on activity-dependent plasticity.https://doi.org/10.1016/j.cell.2025.1...

If you value longevity science without the hype, subscribe to The ReProgram.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 26: GLP-1 Drugs for Longevity

🎬 EPISODE OVERVIEW

A drug millions of people already take extended median lifespan by approximately 12% in older female mice. Does that change the case for GLP-1 drugs as longevity therapies?In this update, Dr. George Murphy reopens The ReProgram Scorecard to examine a new Nature study of late-life semaglutide treatment. He explores the survival findings, improvements in physical and cognitive performance, and the questions that determine how broadly we should interpret the results.How long did the control animals live? How much of the benefit came from eating less? What can a study conducted in females tell us about males—and ultimately humans?The episode also examines new research connecting calorie restriction with DNA mutation accumulation, the challenge of translating mouse biology into human outcomes, and the lessons from semaglutide’s Alzheimer’s trials.The updated assessment: stronger animal evidence and more compelling questions, while the overall grade remains B+.

🔑 KEYWORDS

GLP-1 • Semaglutide • Ozempic • Wegovy • Longevity • Healthy Aging • Calorie Restriction • Somatic Mutations • Healthspan • ReProgram Scorecard

📌 KEY TAKEAWAYS

• The survival finding deserves attention. Median lifespan increased from 742 to 834 days when semaglutide treatment began at 20 months of age and continued throughout life.

• The calorie restriction question remains open. Selected functional outcomes were compared with matched calorie restriction; lifespan was not.

• A benefit in females does not establish a female-specific effect. Males were not tested.

• Historical controls provide context. They cannot replace the controls studied alongside treated animals; replication remains essential.

• The DNA connection is a hypothesis. New calorie restriction research raises questions about mutation accumulation, but does not establish that semaglutide reduces somatic mutations.

• Human outcomes still determine the grade. Strength, mobility, nutrition, cognition, and independence remain central to evaluating longevity interventions.

🎙️ THE REPROGRAM PERSPECTIVE

This study strengthens the reason to investigate GLP-1 therapies in aging. It also sharpens the experiments we need next: replication, direct survival comparisons with calorie restriction, testing both sexes, and meaningful human outcomes.Mechanistic plausibility remains 4.5/5. Human evidence remains 3.5/5. The overall grade stays B+.My interest has increased. My standard of evidence has not changed.

⏱️ CHAPTERS

00:00 A 12% Lifespan Increase: What Does It Mean?

00:36 Revisiting GLP1 Therapies and Longevity

01:12 The New Nature Study

01:28 How Semaglutide Works

01:57 The Survival Result

03:10 The Importance of Starting Age in Treatment

03:57 The Control-Lifespan Debate

05:33 Sex Differences in Longevity Research

06:26 The Calorie Restriction Question

07:35 Calorie Restriction & DNA Mutations

09:01 Translating Mouse Findings to Humans

10:00 Lessons from the Alzheimer’s Trials

11:02 The Updated ReProgram Scorecard

📝 NOTES AND REFERENCES

1. Feng Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657:469–476. The central study discussed in this episode.https://www.nature.com/articles/s41586-026-10940-7

2. Grońska-Pęski M, et al. Caloric restriction modulates genome-wide somatic mutation in mice. Cell. 2026. The calorie restriction and mutation study discussed in the episode.https://doi.org/10.1016/j.cell.2026.08.013

3. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395. A landmark comparison showing that late-life intervention can extend lifespan in both sexes.https://www.nature.com/articles/nature08221

If you value longevity science without the hype, subscribe to The ReProgram.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 25:

🩸 YOUR BLOOD MAY BE AGING BEFORE YOU ARE

🧠 Episode Overview

Blood aging is often overlooked, but the hematopoietic stem cells inside your bone marrow carry a decades-long history.Your blood is not just a fluid; it is a continuously renewing organ system. As the stem cells that manufacture your blood cells age, they can shift immune composition and increase susceptibility to inflammation. This process is central to understanding how systemic aging actually unfolds, moving beyond simple protein panels or biological clocks to look at the cellular machinery that sustains you.We examine the reality of clonal hematopoiesis, known as CHIP, and why it acts as a risk marker rather than a diagnosis. By separating mechanism from marketing, we clarify what parabiosis experiments and plasma exchange can—and cannot—actually achieve in human biology. Understanding blood aging helps us prioritize evidence-based outcomes over the hype of rejuvenation.Subscribe to The ReProgram for scientist-led longevity biology breakdowns, and let us know in the comments if you want a deeper look at specific plasma-related interventions.#BloodAging #LongevityScience #HealthyAging #TheReProgram

🎙️ The ReProgram Perspective

Blood aging forces us to rethink a familiar assumption. The cells circulating today may be new, but their factory - the hematopoietic stem-cell system and its marrow niche - has been shaped by decades of stress, inflammation, mutation, and repair.The biology is compelling because it connects systems that are often discussed separately: immunity, cancer risk, vascular inflammation, tissue repair, and aging. CHIP is a particularly powerful example. A mutation beginning in one stem cell can eventually influence enormous numbers of immune cells and potentially affect organs far beyond the bone marrow.But risk is not destiny, and mechanism is not treatment. CHIP should not be treated as leukemia, a mouse rejuvenation experiment should not be presented as a human anti-aging therapy, and a change in circulating proteins or an aging clock should not be confused with better function, fewer diseases, or longer life.The standard for a credible rejuvenation intervention should be transparent: disclose the intervention, pre-register the trial, define clinically meaningful outcomes, use appropriate controls, report adverse events, and publish the full results. Longevity science moves forward when fascinating biology is tested with standards strong enough to survive the hype around it.

Office Artifact

On the desk: GIANT MICROBES Blood Cells

⏱️ Chapters

00:00 The Blood Factory: Understanding Blood Cell Production

01:26 Aging Blood: Impacts on Health and Disease

02:38 The Role of Stem Cells in Blood Renewal

06:23 Immune Aging: The Complexity of Immune Responses

08:07 Clonal Hematopoiesis: A New Layer of Blood Aging

10:16 The Link Between Blood Aging and Cardiovascular Disease

12:52 Restoring Youth: Potential Strategies for Blood Rejuvenation

16:52 Parabiosis: The Young Blood Experiment

19:40 Plasma exchange: biology versus hype

21:15 Emerging Treatments: The One Generation Approach

25:09 Practical Takeaways: Managing Blood Health

Welcome to The ReProgram.

Longevity science moves a lot slower than longevity marketing.The ReProgram explores the biology of aging, longevity drugs, regenerative medicine, nutrition, exercise, biotechnology, and the emerging science that may help us live longer, healthier lives.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Understand Aging. Build Resilience. Extend Healthspan.

🎬 EPISODE OVERVIEW

Every cell in your body contains essentially the same DNA, yet a neuron behaves nothing like a skin cell. So what actually gives a cell its identity — and how permanent is that identity?In this episode, Dr. George Murphy sits down with epigenetics and cellular reprogramming expert Dr. Jose Polo to explore how cells establish identity, how that identity can be rewritten, and what reprogramming really means for aging and rejuvenation.They discuss why cellular reprogramming is not the same thing as rejuvenation, Jose’s concept of “cell elasticity,” the danger of pushing a cell so far that it loses its identity, and the possibility of using targeted cell conversion as regenerative medicine.

👤 ABOUT THE GUEST

Dr. Jose M. Polo is Director of the Adelaide Centre for Epigenetics in Australia. His research focuses on the transcriptional and epigenetic mechanisms that govern cell identity, pluripotency, cellular reprogramming, early development, and cancer. His laboratory has helped define the molecular sequence of somatic-cell reprogramming, developed strategies for direct cell-fate conversion, and pioneered human iBlastoid models of early embryonic development.Official profile: https://researchers.adelaide.edu.au/p...

🔑 KEYWORDS

Epigenetics • Cellular Reprogramming • Cell Identity • Rejuvenation • Partial Reprogramming • Yamanaka Factors • Induced Pluripotent Stem Cells • Cell Elasticity • Epigenetic Clocks • Regenerative Medicine • iBlastoids • Human Embryo Models • Longevity • Aging

📌 KEY TAKEAWAYS

• Cell identity is regulatory, not genetic. The same genome can produce radically different cell states depending on which programs are active.

• Reprogramming is not the same as rejuvenation. Resetting cellular state may erase age-associated features, but that does not automatically mean restored function.

• “Cell elasticity” may define the safe window for partial reprogramming. A cell can move away from its identity and return — until it crosses a point where that identity may no longer be recoverable.

• Preserving identity is a central safety challenge. A cell that looks younger but loses its specialized function is not a successful rejuvenation strategy.

• Cell-fate control could become medicine. Targeted reprogramming may one day convert resident cells into the cell types needed to repair damaged tissues.

• iBlastoids demonstrate extraordinary human cell plasticity. But they are experimental models — not embryos — and their biological limits matter.

🎙️ THE REPROGRAM PERSPECTIVE

Cellular reprogramming proves that cellular state is not fixed.But making an epigenetic clock move backward is not the same as making a cell healthier.The real goal of rejuvenation should be to restore function and resilience while preserving cell identity, tissue organization, and safety.In longevity science, the most meaningful endpoint is not simply whether a cell looks younger molecularly, but whether it behaves better biologically.

⏱️ CHAPTERS

02:27 Meet Dr. Jose Polo

05:34 What Makes a Cell a Neuron, Skin Cell, or Something Else?

08:15 What Is the Epigenome?

09:43 Reprogramming Is Not the Same as Rejuvenation

11:37 Does Epigenetic Change Cause Aging?

13:16 Cell Elasticity: How Far Can Identity Be Pushed?

14:39 The Danger Zone: Losing Cell Identity

16:48 Reprogramming Cells as Medicine

19:20 How Adult Cells Became Human Embryo Models

22:21 iBlastoids: What They Are — and What They Are Not

23:54 Is Aging a Failure of Cell Identity?

25:27 Can We Erase Bad Epigenetic Memory?

27:07 What We Still Do Not Understand About Reprogramming

📝 NOTES AND REFERENCES

Liu X, Tan JP, Schroder J, et al. Modelling human blastocysts by reprogramming fibroblasts into iBlastoids. Nature. 2021;591:627-632.https://doi.org/10.1038/s41586-021-03...

*If you value longevity science without the hype, subscribe to The ReProgram.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.*